实用医学杂志 ›› 2026, Vol. 42 ›› Issue (12): 2153-2160.doi: 10.3969/j.issn.1006-5725.2026.12.009

• 肿瘤诊治与预后专栏 • 上一篇    

直肠癌化疗耐药患者血浆中环状RNA circGAS5的功能及临床意义

潘子豪,林嘉通,江媚钰,欧小艳,吕泽坚()   

  1. 南方医科大学附属广东省人民医院(广东省医学科学院)普通外科,胃肠外科 (广东 广州 510080 )
  • 收稿日期:2026-03-26 出版日期:2026-06-25 发布日期:2026-06-30
  • 通讯作者: 吕泽坚 E-mail:lvzejian@gdph.org.cn
  • 基金资助:
    国家自然科学基金项目(82373350);国家自然科学基金项目(82573082);国家自然科学基金青年项目(82002508)

Function and clinical significance of circular RNA circGAS5 in plasma of patients with chemoresistant rectal cancer

Zihao PAN,Jiatong LIN,Meiyu JIANG,Xiaoyan OU,Zejian LÜ()   

  1. Department of Gastrointestinal Surgery,Department of General Surgery,Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences),Southern Medical University,Guangzhou 510080,Guangdong,China
  • Received:2026-03-26 Online:2026-06-25 Published:2026-06-30
  • Contact: Zejian Lü E-mail:lvzejian@gdph.org.cn

摘要:

目的 通过检测直肠癌化疗耐药患者外周血中circGAS5的表达水平,探讨该环状RNA(circular RNA, circRNA)在直肠癌化疗耐药中的作用及其诊断化疗耐药的临床价值。 方法 首先通过circRNA芯片测序筛选与直肠癌化疗耐药相关的靶点circGAS5,进一步在肿瘤细胞中采用CCK-8法和克隆形成实验探讨其对直肠癌化疗耐药恶性表型的影响。临床研究纳入44例直肠癌化疗耐药患者与108例化疗敏感患者,采用微滴式数字聚合酶链式反应(ddPCR)检测患者血浆中circGAS5的表达水平。运用t检验、χ2检验、单因素及多因素logistic回归分析、受试者工作特征(receiver operating characteristic,ROC)曲线等统计学方法,分析circGAS5与直肠癌化疗耐药之间的关系。 结果 体外实验结果显示,在化疗耐药的细胞及其培养基中,circGAS5的表达水平显著升高,且其结构稳定性强。临床数据分析显示,直肠癌化疗耐药患者血浆中circGAS5的表达水平显著高于化疗敏感患者(P < 0.001)。多因素logistic回归分析进一步表明,血浆circGAS5高表达是直肠癌化疗耐药的独立危险因素(OR = 3.41,95%CI:2.15 ~ 5.41,P < 0.001)。受试者工作特征曲线评估其诊断效能,结果显示曲线下面积(AUC)为0.827 9,且亚组分析中AUC保持稳定,提示circGAS5具有稳健的诊断价值。功能实验表明,circGAS5可诱导直肠癌细胞化疗耐药恶性表型的进展。 结论 circGAS5可能作为一种有前景的外周血生物标志物,在直肠癌化疗耐药的评估中发挥潜在作用。

关键词: 直肠癌, 环状RNA, 生物标志物, 诊断模型, circGAS5

Abstract:

Objective To investigate the expression level of circGAS5 in the peripheral blood of patients with chemotherapy-resistant rectal cancer and to explore its role in chemotherapy resistance as well as its clinical value in the diagnosis of chemotherapy resistance. Methods A circRNA microarray was initially carried out to screen for circGAS5 as a target associated with chemotherapy resistance in rectal cancer. Subsequently, CCK-8 and colony formation assays were performed in tumor cells to explore its influence on the malignant phenotype of chemotherapy resistance. Clinically, 44 patients with chemotherapy-resistant rectal cancer and 108 patients with chemotherapy-sensitive rectal cancer were recruited. The expression level of circGAS5 in plasma was measured using droplet digital polymerase chain reaction (ddPCR). Statistical analyses, including the t-test, chi-square test, univariate and multivariate logistic regression analyses, and the receiver operating characteristic (ROC) curve, were utilized to assess the relationship between circGAS5 and chemotherapy resistance in rectal cancer. Results In vitro experiments demonstrated that the expression of circGAS5 was significantly up-regulated in chemotherapy-resistant cells and their culture media, and it was accompanied by enhanced structural stability. Clinical data analysis indicated that the plasma expression levels of circGAS5 were significantly higher in patients with chemotherapy-resistant rectal cancer than in those with chemotherapy-sensitive disease (P < 0.001). Multivariate logistic regression analysis further confirmed that high plasma circGAS5 expression was an independent risk factor for chemotherapy resistance (OR = 3.41, 95%CI: 2.15 - 5.41, P < 0.001). ROC curve analysis showed a favorable diagnostic performance with an area under the curve (AUC) of 0.827 9, and the AUC remained stable in subgroup analyses, suggesting the robust diagnostic value of circGAS5. Functional assays showed that circGAS5 promoted the progression of the malignant phenotype associated with chemotherapy resistance in rectal cancer cells. Conclusion circGAS5 may serve as a promising biomarker in peripheral blood for evaluating chemotherapy resistance in rectal cancer.

Key words: rectal cancer, circular RNA, biomarker, diagnostic model, circGAS5